Microcap Ledger Maxcyte, Inc. $MXCT
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Services-Commercial Physical & Biological Research
- Headquarters
- Rockville, MD
- Fiscal year end
- December 31
- Shares outstanding
- 103,206,206 [10-Q 2026-08-13]
What the company doesAI summary of filing
MaxCyte is a commercial cell engineering company that develops and sells Flow Electroporation technology and related instruments to biopharmaceutical companies and academic institutions for discovering, developing, and manufacturing cell and gene therapies. The company generates revenue from sales of its ExPERT instrument platform and disposable processing assemblies, annual licensing fees from research and clinical customers, and milestone and royalty payments from Strategic Platform License agreements with cell therapy developers. The company is revenue-generating and reported over $30 million in cumulative milestone revenue to date, with 31 active Strategic Platform License agreements representing over $2 billion in potential milestone payments. [10-K 2026-03-25]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $16.92M | −$13.62M | −$12.83M | $15.04M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $33.03M | −$44.63M | −$34.41M | $20.07M | [10-K 2026-03-25] |
| FY ended Dec 2024 | $38.63M | −$41.05M | −$27.61M | $27.88M | [10-K 2026-03-25] |
- Quarterly cash burn
- −$6.42M
- Cash runway Estimate
- ~7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 105,482,558 | [10-Q 2024-11-06] |
| 2025-03-07 | 106,027,733 | [10-K 2025-03-11] |
| 2025-05-01 | 106,318,532 | [10-Q 2025-05-08] |
| 2025-08-01 | 106,606,648 | [10-Q 2025-08-06] |
| 2025-11-07 | 106,674,011 | [10-Q 2025-11-13] |
| 2026-03-17 | 106,861,428 | [10-K 2026-03-25] |
| 2026-05-07 | 107,121,672 | [10-Q 2026-05-13] |
| 2026-08-07 | 103,206,206 | [10-Q 2026-08-13] |
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-06-16. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-06-16 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-06-16] |
| 2026-03-20 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-03-20] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-17 | Johnston John Joseph | grant | 30,421 | — | [4 2026-06-22] |
| 2026-06-17 | Hemrajani Rekha | grant | 30,421 | — | [4 2026-06-22] |
| 2026-06-17 | Erck Stanley C | grant | 30,421 | — | [4 2026-06-22] |
| 2026-06-17 | Douglas Richard | grant | 30,421 | — | [4 2026-06-22] |
| 2026-06-17 | Collins Cynthia | grant | 30,421 | — | [4 2026-06-22] |
| 2026-06-17 | Brooke William W | grant | 30,421 | — | [4 2026-06-22] |
| 2026-06-17 | Balthrop Patrick J | grant | 30,421 | — | [4 2026-06-22] |
| 2026-06-17 | Al-Wakeel Yasir B. | grant | 30,421 | — | [4 2026-06-22] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-12 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-08-04 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-07-29 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-17 | 8-K | Shareholder vote results |
| 2026-06-16 | 8-K | Listing notice or transfer |
| 2026-05-14 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-05-12 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-04-29 | DEF 14A | Proxy statement |
| 2026-04-10 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-03-27 | 8-K | Director or officer change |
Alerts for $MXCT
Email me when Maxcyte, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.